A Case of Cicatricial Alopecia Associated with Erlotinib.
10.5021/ad.2011.23.S3.S350
- Author:
Bo Hee YANG
1
;
Chan Yl BANG
;
Ji Won BYUN
;
Sung Hyub HAN
;
Hee Jin SONG
;
Seung Gyun IN
;
Jeong Hyun SHIN
;
Gwang Seong CHOI
Author Information
1. Department of Dermatology, Inha University School of Medicine, Incheon, Korea. garden@inha.ac.kr
- Publication Type:Case Report
- Keywords:
Cicatricial alopecia;
Epidermal growth factor receptor;
Erlotinib
- MeSH:
Acneiform Eruptions;
Alopecia;
Carcinoma, Non-Small-Cell Lung;
Dermatitis, Seborrheic;
Female;
Hair;
Humans;
Middle Aged;
Paronychia;
Protein-Tyrosine Kinases;
Quinazolines;
Receptor, Epidermal Growth Factor;
Skin;
Erlotinib Hydrochloride
- From:Annals of Dermatology
2011;23(Suppl 3):S350-S353
- CountryRepublic of Korea
- Language:English
-
Abstract:
Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.
